Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Conditions
Endometrial Cancer · Gastric Cancer · Metastatic Castration-resistant Prostate Cancer · Ovarian Cancer · Colorectal Cancer · Urothelial Cancer · Biliary Tract Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Research Site, Los Angeles, California, United States
Research Site, San Diego, California, United States
Research Site, Santa Rosa, California, United States
Research Site, Muncie, Indiana, United States
Research Site, Kansas City, Kansas, United States
Research Site, Boston, Massachusetts, United States
Research Site, Boston, Massachusetts, United States
Research Site, Grand Rapids, Michigan, United States
Research Site, East Brunswick, New Jersey, United States
Research Site, Albuquerque, New Mexico, United States
Research Site, Commack, New York, United States
Research Site, Cincinnati, Ohio, United States
Research Site, Columbus, Ohio, United States
Research Site, Portland, Oregon, United States
Research Site, Nashville, Tennessee, United States
Research Site, Nashville, Tennessee, United States
Research Site, Houston, Texas, United States
Research Site, Madison, Wisconsin, United States
Research Site, Toronto, Ontario, Canada
Research Site, Toronto, Ontario, Canada
Research Site, Montreal, Quebec, Canada
Research Site, Montreal, Quebec, Canada
Research Site, Québec, Quebec, Canada
Research Site, Changsha, China
Research Site, Chongqing, China
Research Site, Guangzhou, China
Research Site, Guangzhou, China
Research Site, Guangzhou, China
Research Site, Hangzhou, China
Research Site, Hefei, China
Research Site, Shanghai, China
Research Site, Shanghai, China
Research Site, Shenyang, China
Research Site, Wuhan, China
Research Site, Wuhan, China
Research Site, Xi'an, China
Research Site, Zhengzhou, China
Research Site, Bordeaux, France
Research Site, Lyon, France
Research Site, Marseille, France
Research Site, Suresnes, France
Research Site, Berlin, Germany
Research Site, Essen, Germany
Research Site, Hanover, Germany
Research Site, München, Germany
Research Site, Regensburg, Germany
Research Site, Florence, Italy
Research Site, Genova, Italy
Research Site, Milan, Italy
Research Site, Milan, Italy
Research Site, Milan, Italy
Research Site, Naples, Italy
Research Site, Rome, Italy
Research Site, Chūōku, Japan
Research Site, Kashiwa, Japan
Research Site, Kōtoku, Japan
Research Site, Nagoya, Japan
Research Site, Shinagawa-ku, Japan
Research Site, Suita-shi, Japan
Research Site, Gliwice, Poland
Research Site, Krakow, Poland
Research Site, Lodz, Poland
Research Site, Poznan, Poland
Research Site, Warsaw, Poland
Research Site, Seoul, South Korea
Research Site, Seoul, South Korea
Research Site, Seoul, South Korea
Research Site, Seoul, South Korea
Research Site, Barcelona, Spain
Research Site, Córdoba, Spain
Research Site, Madrid, Spain
Research Site, Málaga, Spain
Research Site, Pamplona, Spain
Research Site, Seville, Spain
Research Site, Basel, Switzerland
Research Site, Bellinzona, Switzerland
Research Site, Sankt Gallen, Switzerland
Research Site, Liou Ying Township, Taiwan
Research Site, Taipei, Taiwan
Research Site, Taipei, Taiwan
Research Site, Taipei, Taiwan
Research Site, Taoyuan, Taiwan
Research Site, Ankara, Turkey (Türkiye)
Research Site, Ankara, Turkey (Türkiye)
Research Site, Cordaleo, Turkey (Türkiye)
Research Site, Edirne, Turkey (Türkiye)
Research Site, Kadıkoy/Istanbul, Turkey (Türkiye)
Research Site, Konya, Turkey (Türkiye)
Research Site, Pamukkale, Turkey (Türkiye)
Research Site, Samsun, Turkey (Türkiye)
Research Site, Cambridge, United Kingdom
Research Site, Dundee, United Kingdom
Research Site, London, United Kingdom
Research Site, London, United Kingdom
Research Site, London, United Kingdom
Research Site, Manchester, United Kingdom
Study leads
Global Clinical Lead, MD
Principal Investigator
AstraZeneca